The Annual Biosimilars Forum event series examines the actual challenges of biosimilar and nanotechnology formulated drug development for research management, leadership and support teams working in and for biosimilar drug development. The event provides a detailed overview of current development issues of follow-on biologics and guidance for their handling.
This year’s event will cover important issues and specific areas of debate facing clinical development teams specialized in bio- and nanosimilar development with a strong focus on statistical and regulatory perspectives. As in previous years, the program of the event will be supported and complemented by leading experts from the fields of regulatory, academic and clinical research.
CALL FOR ABSTRACT SUBMISSIONS
This year the Scientific Programme Committee plans to organize a Contributed Papers section and a Poster section within the Forum.
The organizers are pleased to invite authors to submit abstracts for poster and oral symposium presentations to be delivered at the 3rd Annual Biosimilars Forum.
Email us your Abstract, participate at our 3rd event with your professional work!
At this 3-day series of events we will be focusing on the most actual issues and challenges in bio- and nanosimilar drug development with a strong focus on STATISTICAL and REGULATORY perspectives.
25 OCT, 2018 | COURSES with special lecturers
26 OCT, 2018 | SYMPOSIUM DAY: invited presentations, posters and round table session
27 OCT, 2018 | SEMINAR DAY: Nanotechnology in drug development
SPEAKERS AND LECTURERS
As in previous years, the programme of the event will be supported and complemented by international specialists from the biosimilars and nanosimilars area. The agenda of the forum will continue to expand until October with internationally renowned experts. Some specialists who accepted the invitation to participate at the 3rd Annual Biosimilars Forum (more speakers coming soon):
President of Bawa Biotech LLC; Scientific Advisor at Teva Pharmaceutical Industries, Israel; Founding Director of American Society for Nanomedicine; USA
Professor Emeritus from the University of Toronto, Canada; Former President of Canadian Society for Pharmaceutical Scientists, Canada
Ludwig A. HOTHORN
Professor of Biostatistics at Leibniz Universität Hannover, Faculty of Natural Sciences, Hannover, Germany
Professor of Statistics, Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, UK
European Regulatory Expert; Unit Head, Austrian Medicines and Medical Devices Agency, Austria
Professor of Targeted Nanomedicine at the University of Utrecht; Professor of Targeted Therapeutics at the MIRA Institute of the University of Twente; The Netherlands
Tickets are available now with flexible terms. Please send us your registration as soon as possible because places are limited in number! WBS and ISCB members can attend the 2nd day symposium for free.
Register before 25th of MAY, and get up to 25% EARLY BIRD DISCOUNT from the ticket price!
SCIENTIFIC PROGRAMME COMMITTEE
Vice-Chair, Medicines for Europe, Biosimilar Medicines Group; Head of Clinical Development of Biologics, Gedeon Richter Plc.
Vice Chair, Department Clinical Pharmacology, Medical University of Vienna
Associate Professor, Section for Medical Statistics, Medical Unversity of Vienna
Statistician, Austrian Medicines and Medical Devices Agency; President, Viennese Section of IBS
Chief Scientific Officer, Accelsiors CRO Ltd.; President, Hungarian Society for Clinical Biostatistics
Director Biostatistics for Biostatistics Biosimilars, Analytics group, Novartis
EXCLUSIVE CONTENT – free video lecture series
Sign up and watch all of the presentation videos recorded at the 2nd Biosimilars Forum for free. Learn from the World’s prominent biosimilar drug development experts.
This video lecture series includes the professional courses & lectures delivered at the previous Forum relating to actual issues and challenges of follow-on biologics and guidance for their handling. All the lessons of the 3-part course about the ‘Open issues in the assessment of bioequivalence and biosimilarity’ lectured by Helmut SCHÜTZ are available now.
Bring the Regulators and Producer Companies together into one room is an excellent idea and a beautiful concept.
–Bernd JILMA | Vice Chair, Department Clinical Pharmacology, Medical University of Vienna
I think it’s very nicely covers the whole biosimilar development process… Broader roles could benefit from this conference!
–Ildikó ARADI | Head of Clinical Development of Biologics, Gedeon Richter Plc.
These conferences are extremely useful, they provide discussions in many problems and issues. I hope very much that the series will continue …
–László ENDRÉNYI | Professor Emeritus of Pharmacology and Biostatistics, University of Toronto
The Organizers really done a very good job trying to put together such a conference where we can exchange an idea regarding the regulatory approval process and also on some actual issues in the biosimilar drug development process.
–Shein-Chung CHOW | Professor, Duke University School of Medicine
These meetings, where experts are coming together from the same or different countries bring something new: collaborations, new knowledge, so this is very precious.
–János SZEBENI | Director of the Nanomedicine Research and Education Center at Semmelweis University
The detailed programme of the event will be available soon, until then we recommend you read more about our previous forums!
LEARN MORE ABOUT THE PREVIOUS EVENTS!
At the Annual Biosimilars Forum event series, clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on this key topic of research.
Click on the button below and take a look at the professional lectures of our events, short video interviews with the key speakers, photo galleries and more.
SOME SPEAKERS FROM OUR PREVIOUS FORUMS
Professor, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, USA
Professor Emeritus of Pharmacology and Biostatistics, University of Toronto, Canada
Vice Chair, Department Clinical Pharmacology, Medical University of Vienna, Austria
Unit Head, Austrian Medicines and Medical Devices Agency, Austria
Owner at BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies, Austria
Director of the Nanomedicine Research and Education Center, Semmelweis Medical University, Budapest, Hungary